Database Query Results : , , Pyruv

Pyruv, Pyruvate: Click to Expand ⟱
Source:
Type:
Pyruvate is a small organic molecule that is a key intermediate in several metabolic pathways.
It is the end product of glycolysis, a process that breaks down glucose to release energy.

Increased conversion of pyruvate to lactate (via lactate dehydrogenase, LDH) contributes to the acidification of the tumor microenvironment, which can promote tumor invasion and immune evasion.

Cancer cells can dynamically adjust pyruvate utilization based on nutrient availability. Under certain conditions, some cancer cells may reroute pyruvate to the mitochondria for oxidative phosphorylation, especially in nutrient- or oxygen-rich environments.

This flexibility also means that targeting pyruvate metabolism (e.g., by inhibiting key enzymes like PKM2 or PDKs) is an area of interest in cancer therapy.

Pyruvate is a central metabolite whose handling in cancer cells is redirected to favor increased glycolysis and lactate production over oxidative phosphorylation. This metabolic reprogramming is a key driver of tumor cell survival, proliferation, and adaptation to stress, and is associated with poor prognosis in multiple cancer types. Although not “expressed” like a protein, the regulation of pyruvate metabolism is clearly protumorigenic by sustaining the energetic and biosynthetic demands of cancer, and is an area of active therapeutic exploration.
Scientific Papers found: Click to Expand⟱
1585- Citrate,    Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S - in-vitro, Nor, HEK293
Apoptosis↑, Ferroptosis↑, Ca+2↓, CaMKII ↓, Akt↓, mTOR↓, Hif1a↓, ROS↑, ChemoSen↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Cyt‑c↑, GlucoseCon↓, lactateProd↓, Pyruv↓, GLUT1↓, HK2↓, PFKP↓, Glycolysis↓, Hif1a↓, p‑Akt↓, p‑mTOR↓, Iron↑, lipid-P↑, MDA↑, ROS↑, H2O2↑, mtDam↑, GSH↓, GPx↓, GPx4↓, NADPH/NADP+↓, eff↓, FTH1↓, LC3‑Ⅱ/LC3‑Ⅰ↑, NCOA4↑, eff↓, TumCG↓,
649- EGCG,  CUR,  PI,    Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
*BioEnh↑, EGFR↓, HER2/EBBR2↓, IGF-1↓, MAPK↓, ERK↓, RAS↓, Raf↓, NF-kB↓, p‑pRB↓, TumCCA↑, Glycolysis↓, Warburg↓, HK2↓, Pyruv↓,
1070- IVM,    Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation
- vitro+vivo, GBM, NA
TumCG↓, LC3II↑, p62↓, ATP↓, Pyruv↓, GlucoseCon↑, HK2↓, PFK1↓, GLUT4↓, Glycolysis↓, JAK2↓, p‑STAT3↓, p‑STAT5↓,
2245- MF,    Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis
- in-vitro, Nor, NIH-3T3
Warburg↓, Hif1a↓, *Hif1a∅, Glycolysis↓, *lactateProd↓, *ADP:ATP↓, Pyruv↓, ADP:ATP↓, *PPP↓, *mt-ROS↑, *ROS↓, RPM↑, *ECAR↓,
2251- MF,  Rad,    BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage
- in-vitro, Lung, A549 - in-vitro, HNSCC, UTSCC15 - in-vitro, CRC, DLD1 - in-vitro, PC, MIA PaCa-2
RadioS↑, DNAdam↑, ROS↑, ChemoSen∅, Pyruv↓, ADP:ATP↓, ROS↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx↓, 1,   GPx4↓, 1,   GSH↓, 1,   H2O2↑, 1,   Iron↑, 1,   lipid-P↑, 1,   MDA↑, 1,   NADPH/NADP+↓, 1,   ROS↑, 4,   RPM↑, 1,  

Metal & Cofactor Biology ⓘ

FTH1↓, 1,   NCOA4↑, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↓, 2,   ATP↓, 1,   mtDam↑, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

GlucoseCon↓, 1,   GlucoseCon↑, 1,   Glycolysis↓, 4,   HK2↓, 3,   lactateProd↓, 1,   PFK1↓, 1,   PFKP↓, 1,   Pyruv↓, 5,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   MAPK↓, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↓, 1,   HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

p‑pRB↓, 1,  

Autophagy & Lysosomes ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 1,   p62↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   IGF-1↓, 1,   mTOR↓, 1,   p‑mTOR↓, 1,   RAS↓, 1,   p‑STAT3↓, 1,   p‑STAT5↓, 1,   TumCG↓, 2,  

Migration ⓘ

Ca+2↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   Hif1a↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT4↓, 1,  

Immune & Inflammatory Signaling ⓘ

JAK2↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   ChemoSen∅, 1,   eff↓, 2,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,  
Total Targets: 65

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,   mt-ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ECAR↓, 1,   lactateProd↓, 1,   PPP↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a∅, 1,  

Drug Metabolism & Resistance ⓘ

BioEnh↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: Pyruv, Pyruvate
2 Magnetic Fields
1 Citric Acid
1 EGCG (Epigallocatechin Gallate)
1 Curcumin
1 Piperine
1 Ivermectin
1 Radiotherapy/Radiation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:987  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page